Skip Navigation


NDT Advance Access originally published online on November 7, 2007
Nephrology Dialysis Transplantation 2008 23(2):747-750; doi:10.1093/ndt/gfm488
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/2/747    most recent
gfm488v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sanada, S.
Right arrow Articles by Maeda, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanada, S.
Right arrow Articles by Maeda, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org


Clinical and histological responses of renal amyloidosis to high-dose melphalan supported by autologous stem cell transplantation

Satoru Sanada1,*, Masayuki Suzuki2,*, Tetsuro Shindo2, Saya Suzuki3, Takashi Nakamichi3, Mitsunobu Matsubara1 and Kunihiko Maeda4

1Division of Molecular Medicine, Center for Translational and Advanced Animal Research, Tohoku University School of Medicine, Sendai, 2Department of Internal Medicine, Yamagata Prefectural Central Hospital, Yamagata, 3Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Tohoku University Graduate School of Medicine, Sendai and 4Department of Pathology, Yamagata University School of Medicine, Yamagata, Japan

Correspondence to: Satoru Sanada, Division of Molecular Medicine, Center for Translational and Advanced Animal Research, Tohoku University School of Medicine, Seiryouchou 2-1, Aoba-ku, Sendai 980-0875 Japan. Email: sasanada@mail.tains.tohoku.ac.jp

Keywords: high-dose melphalan; primary amyloidosis; renal biopsy; stem cell transplantation

The first 150 words of the full text of this article appear below.



   Introduction
 
Primary amyloidosis (AL) is a clonal plasma cell dyscrasia. Monoclonal immunoglobulin light or heavy chain fragments produced by abnormal plasma cells deposit in multiple organs, such as the kidneys, heart and gastrointestinal tract, resulting in severe multi-organ dysfunction. The principal clinical manifestation due to renal involvement is massive proteinuria, which leads to nephrotic syndrome and subsequent renal failure [1,2]. The therapeutic strategy for AL has progressed in parallel with that of multiple myeloma (MM), which is a malignant type of plasma cell disorder. Recently, high-dose chemotherapy with autologous stem cell transplantation (HDT/SCT) has been applied to MM, with a much better outcome than conventional therapy [3]. Thus, this therapy has been further applied to AL, and meta-analysis reveals that ~50–75% of renal AL patients treated with HDT/SCT showed more than 50% reduction in proteinuria [4,5].

In spite of many reports . . . [Full Text of this Article]



   Case
 
Clinical course until first renal biopsy
Pathological findings in first renal biopsy (Figure 1A and B)
HDT/SCT therapy and following clinical course
Pathological findings of second renal biopsy (Figure 1C and D)
Quantitative analysis of amyloid deposition in the glomeruli (Figure 2)


   Discussion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?